Literature DB >> 8643511

Hemodynamic effects of epidermal growth factor in conscious rats and monkeys.

J A Keiser1, M J Ryan.   

Abstract

The therapeutic application of growth factors to human disease has become closer to reality with the advent of faster means of synthesizing these molecules and novel drug delivery strategies. Epidermal growth factor (EGF) belongs to a large family of molecules with the ability to modulate growth. Purified extracts of EGF have been used clinically to modulate gastrointestinal secretion of hormones and accelerate healing. EGF is also reported to have both vascular smooth muscle contractile and relaxing activity Cardiovascular studies were performed with the bioactive 48-amino acid fragment of human EGF in rodents and primates to determine the effects of EGF on blood pressure and heart rate in conscious animals. Intravenous infusion of EGF induced an initial pressor response in rats followed by a prolonged decrease in blood pressure. In contrast, in monkeys, EGF had dose-related blood pressure-lowering effects only; significant hypotension was observed at doses ranging from 3 to 300 microg/kg i.v. Hypotension was associated with modest tachycardia in both species. To our knowledge, this is the first report of hemodynamic effects of EGF in primates, and it clearly documents that the mitogenic role of growth factors such as EGF is but one aspect of their physiology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8643511      PMCID: PMC39387          DOI: 10.1073/pnas.93.10.4957

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Effect of h-EGF and h-EGF 1-48 on histamine-stimulated gastric acid secretion in rats and monkeys.

Authors:  A Guglietta; C A Lesch
Journal:  J Physiol Paris       Date:  1993

2.  Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice.

Authors:  K Kawaida; K Matsumoto; H Shimazu; T Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

3.  Epidermal growth factor is a potent inhibitor of renin secretion.

Authors:  I Antonipillai
Journal:  Hypertension       Date:  1993-05       Impact factor: 10.190

4.  Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats.

Authors:  S B Miller; D R Martin; J Kissane; M R Hammerman
Journal:  Am J Physiol       Date:  1994-01

5.  Vascular smooth muscle relaxation induced by epidermal growth factor is endothelium-dependent.

Authors:  A Namiki; N Akatsuka
Journal:  Eur J Pharmacol       Date:  1990-05-16       Impact factor: 4.432

6.  Fluid balance, electrolyte profiles and plasma parathyroid hormone concentrations in ewes treated with epidermal growth factor.

Authors:  C B Gow; M Wilkinson; M J Silvapulle; G P Moore
Journal:  J Endocrinol       Date:  1992-10       Impact factor: 4.286

7.  Ligand binding characterization and molecular analysis of distinct epidermal growth factor-urogastrone receptors in cultured smooth muscle and epithelial cells from guinea pig intestine.

Authors:  S G Yang; S Ahmad; N C Wong; M D Hollenberg
Journal:  Mol Pharmacol       Date:  1994-08       Impact factor: 4.436

8.  Epidermal growth factor accelerates renal tissue repair in a model of gentamicin nephrotoxicity in rats.

Authors:  N J Morin; G Laurent; D Nonclercq; G Toubeau; J A Heuson-Stiennon; M G Bergeron; D Beauchamp
Journal:  Am J Physiol       Date:  1992-11

9.  Exogenous epidermal growth factor fails to accelerate functional recovery in the autotransplanted ischemic pig kidney.

Authors:  D Killion; C Canfield; J Norman; J T Rosenthal
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

10.  Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model.

Authors:  T A Mustoe; G F Pierce; C Morishima; T F Deuel
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

View more
  1 in total

1.  Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.

Authors:  Katherine A Vallis; Raymond M Reilly; Deborah Scollard; Pat Merante; Anthony Brade; Sobi Velauthapillai; Curtis Caldwell; Ida Chan; Marc Freeman; Gina Lockwood; Naomi A Miller; Bart Cornelissen; Jennifer Petronis; Kathryn Sabate
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.